Results 51 to 60 of about 687 (166)

Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 6, Page 1134-1142, June 2025.
In this systematic review and network meta‐analysis of Janus kinase (JAK) inhibitors for alopecia areata (AA), no evidence of a difference between ritlecitinib 50 mg and baricitinib 4 mg on Severity of Alopecia Tool (SALT) ≤10 (odds ratio,OR: 0.96, 95% credible interval,CrI: 0.18–7.21) and SALT ≤20 (OR: 1.19, 95% CrI: 0.23–10.67) at Week 24 was found ...
D. Aceituno, C. G. Fawsitt, G. M. Power, E. Law, S. Vaghela, H. Thom   +5 more
wiley   +1 more source

Successful Therapy of Alopecia Universalis Using a Combination of Systemic Methotrexate and Corticosteroids and Topical 5% Minoxidil

Clinical, Cosmetic and Investigational Dermatology, 2022
Kartika Ruchiatan, Erda Avriyanti, Reti Hindritiani, Diah Puspitosari, Oki Suwarsa, Hendra Gunawan Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr.
Ruchiatan K, Avriyanti E, Hindritiani R, Puspitosari D, Suwarsa O, Gunawan H   +5 more
doaj  

SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Ziad Reguiai, Leila Asfour, Delphine Staumont‐Sallé, Ángela Hermosa‐Gelbard, Andrea Sechi, Dalia Wajsbrot, Rahmat Ishowo‐Adejumo, Deborah Woodworth, Alexandre Lejeune   +8 more
wiley   +1 more source

Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 6, Page 1152-1162, June 2025.
ALLEGRO‐LT (NCT04006457) is an open‐label, phase 3 study investigating the long‐term safety and efficacy of ritlecitinib in patients with alopecia areata (AA). In this analysis in 449 de novo patients with AA and ≥25% scalp hair loss, ritlecitinib demonstrated clinical efficacy and had an acceptable safety profile through Month 24.
C. Tziotzios, R. Sinclair, A. Lesiak, S. Mehlis, M. Kinoshita‐Ise, A. Tsianakas, X. Luo, E. H. Law, R. Ishowo‐Adejumo, R. Wolk, M. Sadrarhami, A. Lejeune   +11 more
wiley   +1 more source

Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database

Dermatology and Therapy, 2023
Introduction Alopecia areata (AA) is an autoimmune disease with an underlying immuno-inflammatory pathogenesis. Treatments can include systemic corticosteroids and immunomodulators (such as Janus kinase inhibitors); these medications may be associated ...
Prethibha George, Oladayo Jagun, Qing Liu, Charles Wentworth, Lynne Napatalung, Robert Wolk, Susan Anway, Samuel H. Zwillich   +7 more
doaj   +1 more source

Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 6, Page 1163-1173, June 2025.
A post hoc analysis of Severity of Alopecia Tool (SALT) score trajectories in patients with alopecia areata who received ritlecitinib 50 mg once‐daily in ALLEGRO‐2b/3 and rolled over into the ongoing, open‐label, Phase 3 ALLEGRO‐LT study. Long‐term response patterns up to Month 24 and variables associated with treatment response are described. Abstract
B. King, P. Mirmirani, K. Lo Sicco, Y. Ramot, R. Sinclair, L. Asfour, K. Ezzedine, C. Paul, M. Ohyama, R. A. Edwards, G. Bonfanti, U. Kerkmann, D. Wajsbrot, R. Ishowo‐Adejumo, S. H. Zwillich, A. Lejeune   +15 more
wiley   +1 more source

Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor

Journal of Inflammation Research, 2023
Yan Teng,1 Yibin Fan,1 Danying Shang,1 Xiaohua Tao,1,* Dongsheng Sun2,* 1Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou ...
Teng Y, Fan Y, Shang D, Tao X, Sun D
doaj  

Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 6, Page 1174-1184, June 2025.
Patients with alopecia areata received etrasimod 2 mg, 3 mg or placebo oncedaily for 24 weeks, followed by a 28‐week open‐label extension period. Overall, etrasimod 2 mg and 3 mg were safe and well tolerated in patients; their efficacy was numerically higher than placebo and appeared to be dose dependent.
B. King, N. Mesinkovska, M. Senna, X. Luo, J. Minkiewicz, A. Selfridge   +5 more
wiley   +1 more source

Alopecia Areata: Pathogenesis, Diagnosis, and Therapies

MedComm, Volume 6, Issue 5, May 2025.
This review probed into the immune factors in the pathogenesis of AA, focusing on the small molecule drugs and biologics for the treatment of AA, and anticipated the research direction in terms of the pathogenesis and targeted therapy of AA. It aims to emphasize the necessity for further exploration of its immunological pathogenesis and therapeutic ...
Tianyou Ma, Tingrui Zhang, Fengze Miao, Jun Liu, Quangang Zhu, Zhongjian Chen, Zongguang Tai, Zhigao He   +7 more
wiley   +1 more source

ALOPECIA UNIVERSAL COMO PRESENTACIÓN INICIAL DE UN SÍNDROME POLIGLANDULAR AUTOINMUNE REPORTE DE CASO

Medicina, 2018
Introducción: La alopecia universalis es la pérdida de pelo en todo el cuerpo por destrucción del folículo capilar. En la etiología se describen factores 1. Genéticos como alteración del cromosoma 18, haplotipos HLA DQ3, DQ7, DR4 y DR11. 2.
Liliana M. Mejía Zapata, Angie M. Cárdenas Silva   +1 more
doaj